Biotech Startup Licenses Technology From UCSD, Raises $18M
A new, biotech startup focused on delivery of nucleic acid therapeutics, Solstice Biologics, said last week that it has licensed technology developed at UC San Diego, and received $18M in a Series A funding. Solstice, which is based in San Francisco, said the technology was licensed from the University of California, San Diego, and is based on research from Professor Steven Dowdy , Ph.D., and his colleagues at UC San Diego School of Medicine. The funding round was led by venBio, and also included Aeris Capital.
posted on Monday, January 7, 2013 (Link to more information)

Related companies:
Biotech Healthcare Partners

Related stories:
> UCSD Ties With Agilent On Photonics Testing
> SANYO, UCSD In Research Deal
> GrollTex Gets Seed Funding
> UCSD Initiative Forms Storage Advisory Board
> ViaSat, UCSD Team On Live Sports Streaming Home